The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
Open accessAbstract
Background: Digital healthcare systems data could provide insights into the global prevalence of chronic kidney disease (CKD). We designed the CaReMe CKD study to estimate the prevalence, key clinical adverse outcomes and costs of CKD across 11 countries. Methods: Individual-level data of a cohort of 2·4 million contemporaneous CKD patients was obtained from digital healthcare systems in participating countries using a pre-specified common protocol; summarized using random effects meta-analysis. CKD and its stages were defined in accordance with current Kidney Disease: Improving Global Outcomes (KDIGO) criteria. CKD was defined by laboratory values or by a diagnosis code. Findings: The pooled prevalence of possible CKD was 10·0% (95% confidence interval 8.5‒11.4; mean pooled age 75, 53% women, 38% diabetes, 60% using renin-angiotensin-aldosterone system inhibitors). Two out of three CKD patients identified by laboratory criteria did not have a corresponding CKD-specific diagnostic code. Among CKD patients identified by laboratory values, the majority (42%) were in KDIGO stage 3A; and this fraction was fairly consistent across countries. The share with CKD based on urine albumin-creatinine ratio (UACR) alone (KDIGO stages one and two) was 29%, with a substantial heterogeneity between countries. Adverse events were common; 6·5% were hospitalized for CKD or heart failure, and 6·2% died, annually. Costs for renal events and heart failure were consistently higher than costs for atherosclerotic events in CKD patients across all countries. Interpretation: We estimate that CKD is present in one out of ten adults. These individuals experience significant adverse outcomes with associated costs. The prevalence of CKD is underestimated when using diagnostic codes alone. There is considerable public health potential in diagnosing CKD and providing treatments to those currently undiagnosed. Funding: The study was sponsored by AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
De Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,030
The global burden of chronic kidney disease: estimates, variability and pitfalls
Glassock, R. J., Warnock, D. G., & Delanaye, P. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.163 · Cited by 511
Birkeland, K. I., Bodegard, J., Eriksson, J. W., Norhammar, A., Haller, H., Linssen, G. C. M., Banerjee, A., Thuresson, M., Okami, S., Garal‐Pantaler, E., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14074 · Cited by 223
Self-citationAll-cause costs increase exponentially with increased chronic kidney disease stage.
Golestaneh, L., Alvarez, P. J., Reaven, N. L., et al. (2017) · PubMed · Cited by 139
Birkeland, K. I., Bodegård, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., Thuresson, M., Okami, S., Ha, K. H., Kossack, N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14189 · Cited by 56
Self-citationEscobar, C., Aranda, U., Palacios, B., Capel, M., Sicras, A., Sicras, A., Hormigo, A., Arroyo, R. A., Manito, N., & Botana, M. (2021) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.01.008 · Cited by 32
Self-citation
Metadata
- Authors
- Sundström, J., Bodegard, J., Bollmann, A., Vervloet, M. G., Mark, P. B., Karasik, A., Taveira-Gomes, T., Botana, M., Birkeland, K. I., Thuresson, M., Jäger, L., Sood, M. M., VanPottelbergh, G., & Tangri, N.
- Venue
- The Lancet Regional Health - Europe
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 20
- Pages
- 100438
- ISSN
- 2666-7762 (ISSN-L)
- OpenAlex
- W4283747762
- Cited by
- 323
- References
- 11
- FWCI
- 37.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. https://app.cochat.ai/papers/10.1016/j.lanepe.2022.100438
- The paper
- Sundström, J., Bodegard, J., Bollmann, A., Vervloet, M. G., Mark, P. B., Karasik, A., Taveira-Gomes, T., Botana, M., Birkeland, K. I., Thuresson, M., Jäger, L., Sood, M. M., VanPottelbergh, G., & Tangri, N. (2022). Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2022.100438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.